Novel PET radiotracer can help in early diagnosis of atherosclerosis: Study
Denmark: Results from a recent study published in the journal Atherosclerosis could pave way for a new approach for the early diagnosis of atherosclerosis. The study found that a novel PET radiotracer can visualize immune cell activity in the artery walls of the patients.
"Urokinase-type plasminogen activator receptor (uPAR) is expressed abundantly by mononuclear phagocyte system (MPS) cells in the atherosclerotic plaques and can be visualized by the experimental positron emission tomography (PET) tracer [64Cu]Cu-DOTA-AE105," Harshvardhan A. Khare, University of Copenhagen, Copenhagen, Denmark, and colleagues wrote in their study. "This may help in non-invasive detection of extracellular matrix (ECM) remodeling during atherogenesis.
uPAR is shown to be associated with the degradation of the extracellular matrix and cancer aggressiveness. However, there is no clarity on its role in arterial atherogenesis as a molecular imaging target. Dr. Khare and colleagues, therefore, aimed to non-invasively visualize uPAR expression in atherosclerosis by a novel uPAR-targeting PET tracer.
Molecular biology was used to examine uPAR expression by analyzing human atherosclerotic plaques and cultured cells. The researchers then performed a retrospective analysis on patients who underwent combined PET/CT (n = 10) to measure [64Cu]Cu-DOTA-AE105 uptake in five large arteries, divided into a high and low-risk group based on coronary artery calcium score (CAC score).
The findings of the study were as follows:
· The in vitro assay for THP-1 monocytes displayed a significantly upregulated uPAR expression upon stimulation (5.2-fold upregulation) by single-cell flow cytometric analysis.
· Freshly excised human atherosclerotic plaques underwent flow cytometric and microarray analyses manifesting 73.9 ± 2.9% of mononuclear phagocyte system (MPS) cells expressing uPAR and had a greater than 7-fold higher gene expression of plasminogen activator urokinase receptor (PLAUR), integrin subunit alpha X (ITGAX), and cluster of differentiation 163 (CD163).
· The tissue-to-background ratios (TBRmax) in five large arteries showed a higher [64Cu]Cu-DOTA-AE105 uptake in the group with a high CAC score compared to the group with low CAC score (2.4 ± 0.1 vs 1.7 ± 0.1), significantly higher in the ascending aorta (2.7 ± 0.1 vs 2.0 ± 0.1) and the abdominal aorta (3.2 ± 0.2 vs 2.0 ± 0.2) by a non-parametric Mann-Whitney test.
The researchers provided in vitro and ex vivo evidence to confirm that uPAR can be visualized in vivo non-invasively and is associated with vascular remodeling resulting from ECM restructuring occurring during the atherosclerosis progression.
Reference:
The study titled, "In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [64Cu]Cu-DOTA-AE105 positron emission tomography (PET)," was published in the journal Atherosclerosis.
DOI: https://doi.org/10.1016/j.atherosclerosis.2022.03.026
KEYWORDS: Atherosclerosis journal, atherosclerosis, PET, positron emission tomography, radiotracer, early diagnosis, molecular imaging, mononuclear phagocyte system, urokinase-type plasminogen activator receptor, Harshvardhan A Khare, atherogenesis, extracellular matrix
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.